Kyowa Kirin stops development of skin condition treatment

Company Overview - Kyowa Kirin has announced the discontinuation of all ongoing trials for its experimental drug rocatinlimab, which was intended to treat skin conditions such as moderate-to-severe atopic dermatitis and prurigo nodularis, as well as moderate-to-severe asthma [1] - The decision to halt the development was made following a recent safety update from the global rocatinlimab clinical program, indicating that potential risks may outweigh the benefits for patients [1] Collaboration and Control - Earlier in the year, Kyowa Kirin terminated its development and commercialization collaboration for rocatinlimab with Amgen [1] - Following this termination, Kyowa Kirin will take control of the global rocatinlimab program, including regulatory filings and future commercialization efforts [1]